Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases
Virologica Sinica · 2023
DOI: 10.1016/j.virs.2023.07.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Virologica Sinica, 2023. Verfasst von Yongmei Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Med…. Hauptthemen laut MEDLINE: COVID-19, Liver Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality, Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park, National Key Research and Development Program of China.
Abstract (Originalsprache)
Chronic liver disease (CLD) entails elevated risk of COVID-19 severity and mortality. The effectiveness of the booster dose of inactivated SARS-CoV-2 vaccine in stimulating antibody response in CLD patients is unclear. Therefore, we conducted a cross-sectional study involving 237 adult CLD patients and 170 healthy controls (HC) to analyze neutralizing antibodies (NAbs) against SARS-CoV-2 prototype and BA.4/5 variant, anti-receptor binding domain (RBD) IgG, and total anti-SARS-CoV-2 antibodies. Serum levels of the total anti-SARS-CoV-2 antibodies, anti-RBD IgG and inhibition efficacy of NAbs were significantly elevated in CLD patients after the booster dose compared with the pre-booster dose, but were relatively lower than those of HCs. Induced humoral responses decreased over time after booster vaccination. The neutralization efficiency of the serum against BA.4/5 increased but remained below the inhibition threshold. All four SARS-CoV-2 antibodies, including total anti-SARS-CoV-2 antibodies, anti-RBD IgG and NAbs against prototype and BA.4/5, were lower in patients with severe CLD than those with non-severe CLD. After booster shot, age and time after the last vaccine were the risk factors for seropositivity of NAb against BA.4/5 in CLD patients. Additionally, white blood cell counts and hepatitis B core antibodies were the protective factors, and severe liver disease was the risk factor associated with seropositivity of total anti-SARS-CoV-2 antibodies. Overall, our data uncovered that antibody responses were improved in CLD patients and peaked at 120 days after the booster vaccines. All antibodies excepting total anti-SARS-CoV-2 antibodies declined after peak. CLD patients exhibited impaired immunologic responses to vaccination and weakened NAbs against BA.4/5, which hindered the protective effect of the booster shot against Omicron prevalence. Cellular immune responses should be further evaluated to determine the optimal vaccine regimen for CLD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730,…
- Department of Clinical Laboratory, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, 050021, China.
- Division of Liver Diseases, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, 050021, China.
- Division of Liver Diseases, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, 050021, China. Electronic address: daieh2008@126.com.
Förderung
- Natural Science Foundation of Beijing Municipality
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- National Key Research and Development Program of China
- Hebei Provincial Key Research Projects
Zitieren
APA
Liu, Y., Lu, J., Zhan, H., Yuan, W., Li, X., Kang, H., Li, H., Chen, Y., Cheng, L., Sun, X., Zheng, H., Wang, W., Dai, E., & Li, Y. (2023). Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases. Virologica Sinica. https://doi.org/10.1016/j.virs.2023.07.005
Vancouver
Liu Y, Lu J, Zhan H, Yuan W, Li X, Kang H, et al. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases. Virologica Sinica. 2023. doi:10.1016/j.virs.2023.07.005
BibTeX
@article{Liu2023,
author = {Liu, Yongmei and Lu, Jianhua and Zhan, Haoting and Yuan, Wenfang and Li, Xiaomeng and Kang, Haiyan and Li, Haolong and Chen, Yongliang and Cheng, Linlin and Sun, Xingli and Zheng, Haojie and Wang, Wei and Dai, Erhei and Li, Yongzhe},
title = {Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases},
journal = {Virologica Sinica},
year = {2023},
doi = {10.1016/j.virs.2023.07.005}
}
EUVIMED